期刊文献+

2010年美国临床肿瘤学会年会热点——小细胞肺癌的研究进展 被引量:4

Advances of Treatment of Small Cell Lung Cancer in 2010 American Society of Clinical Oncology Annual Meeting
下载PDF
导出
摘要 从生物学行为的角度可将肺癌分为小细胞肺癌(small cell lung cancer,SCLC)和非小细胞肺癌(non-small cell lung cancer,NSCLC),其中SCLC约占15%左右。SCLC恶性程度高,虽然对放疗、化疗较敏感,但预后差[1]。本文就2010年美国临床肿瘤学会(American Society of Clinical Oncology,ASCO)年会上有关SCLC的研究进展做一综述。
出处 《中国肺癌杂志》 CAS 2010年第9期913-916,共4页 Chinese Journal of Lung Cancer
基金 浙江省医药卫生科学研究基金计划项目(No.2010KYA035) 浙江省中医药科学研究基金计划(No.2010ZA006)资助~~
  • 相关文献

参考文献15

  • 1Hanna N, Bunn PA, Langer C, et al. Randomized phase Ⅲ trial comparing Irinotecan/Cisplatin with Etoposide/Cisplatin in patients with previously untreated extensive-stage disease small-cell lung Cancer. J Clin Oncol, 2006, 24(13): 2038-2043.
  • 2Jeong J, Sung J, Pyo H, et al. Retrospective study of irinotecan plus cisplatin induction followed by concurrent thoracic irradiation with irinotecan plus cisplatin chemotherapy for limited-disease small cell lung cancer. J Clin Oncol, 2010, 28(suppl): 7053.
  • 3Comely OA, Wolf J, Josten KM, et al. Sabarubicin (SABA) in combination with cisplatin DDP): Maximum tolerated dose (MTD) evaluation (phase Ⅰ step) followed by a phase Ⅱ step in patients (pts) with small cell lung cancerextensive disease (SCLC-ED).J Clin Oncol, 2010, 28(Suppl): 7048.
  • 4Brien MO, Jassem J, Lorigan P, et al. Randomized phase Ⅱ study (EORTC 08062) of amrubicin as single agent or in combination with cisplatin versus etoposide-cisplatin as first-line treatment in patients (pts) with extensive disease small cell lung cancer (ED SCLC). J Clin Oncol, 2010, 28(Suppl): 7052.
  • 5Lubiner ET, Spigel DR, Greco FA, et al. Phase Ⅱ study ofirinotecan and carboplatin followed by maintenance sunitinib in the first-line treatment of extensive-stage small cell lung cancer.J Clin Oncol, 2010, 28(Suppl): 7049.
  • 6Ready N, Dunphy F, Pang H, et al. Combination chemotherapy with sunitinib (IND 74019; NSC 736511) for untreated extensive-stage small cell lung cancer (SCLC): CALGB 30504 phase IB safety results. J Clin Oncol, 2010, 28(Suppl): 7056.
  • 7Yee D, Butts CA, Chu QS, et al. Phase II trial of consolidation chest radiotherapy for extensive-stage small cell lung cancer. J Clin Oncol, 2010, 28 (Suppl): 7044.
  • 8Zarogoulidis K, Eleftheriadou E, Gerasimou G, et al. Long-acting somatostatin analogues survival differences in limited- and extensive-disease SCLC patients. J Clin Oncol, 2010, 28(Suppl): 7051.
  • 9Ciuleanu T, Samarzjia M, Demidchik Y, et al. Randomized phase Ⅲ study (SPEAR) ofpicoplatin plus best supportive care (BSC) or BSC alone in patients (pts) with SCLC refractory or progressive within 6 months after first-line platinum-based chemotherapy. J Clin Oncol, 2010, 28(Suppl): 7002.
  • 10Hirose T, Shirai T, Kusumoto S, et al. Phase Ⅱ study of amrubicin and carboplatin in patients with the refractory or relapsed small cell lung cancer (SCLC). J Clin Oncol, 2010, 28 (Suppl): 7057.

同被引文献28

引证文献4

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部